Current Status of and Challenges in Diagnosis and Treatment of Childhood Diffuse Parenchymal Lung Diseases/Childhood Interstitial Lung Diseases

CHEN Hui-zhong

Abstract

The medical field in China has witnessed encouraging progress in specialized theoretical research and clinical practice concerning childhood diffuse parenchymal lung diseases/childhood interstitial lung diseases (chDPLD/chILD) after many years of hard work. However, we have also encountered many tasks and challenges. We must approach the problem with a holistic perspective, and collect, accumulate and analyze, in a uniform way, the data from all over the country. We should try our best to obtain more pathological materials for further analysis of the diagnosis and treatment as well as clinical research. The diagnosis protocol and treatment recommendations should be revised regularly. Moreover, we emphasize the adoption of the clinico-radio-genetic-pathological (C-R-G-P) management model and the multi-disciplinary team (MDT) approach to the diagnosis and treatment of chDPLD/chILD. In this way, we will be able to improve our cognitive understanding and enrich our experience in the prevention and management of chDPLD/chILD further more.

 

Keywords: Diffuse parenchymal lung diseases/interstitial lung diseases, Current status and challenges, Diagnosis and treatment, Childhood

 

Full Text:

PDF


References


DISHOP M K. Dishop paediatric interstitial lung disease: classification and definitions. Paediatr Respir Rev，2011，12(4): 230–237.

RICE A， TRAN-DANG M， BUSH A， et al. Diffuse lung disease in infancy and childhood: expanding the chILD classification. Histopathology，2013，63(6): 743–755.

American Thoracic Society， European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med，2002，165(2): 277–304.

TRAVIS W D， COSTABEL U， HANSELL D M， et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med，2013， 188(6): 733–748.

DEUTSCH1 G H， YOUNG L R， DETERDING R R， et al. Diffuse lung disease in young children application of a novel classification scheme. Am J Respir Crit Care Med，2007，176(11): 1120–1128.

CLEMENT A， NATHAN N， EPAUD R， et al. Interstitial lung diseases in children. Orphanet J Rare Dis， 2010， 5: 22[2021-03-06]. https://ojrd. biomedcentral.com/articles/10.1186/1750-1172-5-22. doi: 10.1186/1750-1172-5-22.

XU D， CHEN Z M， CHEN H Z， et al. Application of clinico-radiologic-pathologic diagnosis of diffuse parenchymal lung diseases in children in China. PLoS One， 2015， 10(1): e0116930[2021-03-06] https://doi.org/ 10.1371/journal.pone.0116930.

CHEN J， NONG G， LIU X， et al. Genetic basis of surfactant dysfunction in Chinese children: A retrospective study. Pediatr Pulmonol，2019，54(8): 1173–1181.

ZHANG G， CAO L. New mutations in the SLC7A7 gene of two chinese sisters with lysinurie protein intolerance. Pediatr Pulmonol，2017，52(11): E94–E96.

KURLAND G， DETERDING R R， HAGOOD J S， et al. An Official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med，2013，188(3): 376–394.

BUSH A， CUNNINGHAM S， DE BLIC J， et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax，2015，70(11): 1078–1084.

TANG X， SHEN Y， ZHOU C， et al. Surfactant protein C dysfunction with new clinical insights for diffuse alveolar hemorrhage and autoimmunity. Pediatric Investigation，2019，3(4): 201–206.

TANG X， LI H， LIU H， et al. Etiologic spectrum of interstitial lung diseases in Chinese children older than 2 years of age. Orphanet J Rare Dis，2020，15(1): 25–35.

JOLY B S， SIGURET V， VEYRADIER A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med，2020，46(8): 1603–1606.

CUNNINGHAM S， JAFFE A， YOUNG L R. Children’s interstitial and diffuse lung disease. Lancet Child Adolesc Health，2019，3(8): 568–577.

RAVAGLIA C， BONIFAZI M， WELLS A U， et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: A comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration，2016，91(3): 215–227.


Refbacks

  • There are currently no refbacks.